Q-omics provides the consensus-scored TRIM17 profile across patient tissues and cancer cell-line models. TRIM17 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, TRIM17 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, TRIM17 RNA expression shows 18,821 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight READ, BLCA, and THYM as cancer lineages where TRIM17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM17 survival associations across molecular data types. TRIM17 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM17 RNA expression–survival associations across cancer types. High TRIM17 expression shows unfavorable associations in KIRC, LIHC and COAD, but favorable associations in READ, HNSC and LGG. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for TRIM17 RNA expression.
This table summarizes TRIM17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM17 shows lower tumor expression in KICH and KIRC and higher tumor expression in BLCA, LIHC, THCA and CHOL. The BLCA box plot shows higher TRIM17 RNA expression in tumor versus normal tissue (log2 FC = +1.403, t-test p < 0.001).
This table shows molecular features associated with TRIM17 in patient tissues and cancer cell lines. In patient samples, TRIM17 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
